Clinical investigation for the establishment of predictive marker for therapy-related cardiovascular adverse events onset in hematologic malignancies.

Clinical investigation for the establishment of predictive marker for therapy-related cardiovascular adverse events onset in hematologic malignancies. - Relationship between the treatment in hematological malignancies and endothelial progenitor cells (EPC)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028091

Enrollment

Registered

2017-07-06

Start date

2017-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignancies

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients diagnosed with hematologic malignancies and who will be treated by the therapy which can cause cardiovascular adverse events onset at Akita university hospital.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Correlation between the changes of xanthine oxidase activity, the absolute number of EPC in peripheral blood and the cardiovascular adverse events onset	—

Countries

Japan

Contacts

Public ContactTakahiro Kobayashi

Akita University Graduate School of Medicine Department of Hematology, Nephrology, Rheumatology,

takahiro@med.akita-u.ac.jp018-884-6116

Outcome results